Foghorn Therapeutics Inc.
FHTX
$4.44
$0.153.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.89% | 26.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.89% | 26.97% | |||
| Cost of Revenue | -8.21% | 0.77% | |||
| Gross Profit | 16.76% | 9.18% | |||
| SG&A Expenses | -3.06% | -5.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.98% | -0.73% | |||
| Operating Income | 12.31% | 7.93% | |||
| Income Before Tax | 11.64% | 4.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.64% | 4.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.64% | 4.77% | |||
| EBIT | 12.31% | 7.93% | |||
| EBITDA | 12.83% | 8.33% | |||
| EPS Basic | 11.69% | 4.97% | |||
| Normalized Basic EPS | 11.69% | 4.97% | |||
| EPS Diluted | 11.69% | 4.97% | |||
| Normalized Diluted EPS | 11.69% | 4.97% | |||
| Average Basic Shares Outstanding | 0.08% | 0.21% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||